These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7497596)

  • 1. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.
    Launay-Iliadis MC; Bruno R; Cosson V; Vergniol JC; Oulid-Aissa D; Marty M; Clavel M; Aapro M; Le Bail N; Iliadis A
    Cancer Chemother Pharmacol; 1995; 37(1-2):47-54. PubMed ID: 7497596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.
    Bruno R; Vivier N; Vergniol JC; De Phillips SL; Montay G; Sheiner LB
    J Pharmacokinet Biopharm; 1996 Apr; 24(2):153-72. PubMed ID: 8875345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
    Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
    Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
    Bruno R; Riva A; Hille D; Lebecq A; Thomas L
    Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S16-9. PubMed ID: 9435928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.
    Ferron GM; Dai Y; Semiond D
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):681-92. PubMed ID: 23299792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the linearity of docetaxel pharmacokinetics.
    McLeod HL; Kearns CM; Kuhn JG; Bruno R
    Cancer Chemother Pharmacol; 1998; 42(2):155-9. PubMed ID: 9654116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of docetaxel.
    Clarke SJ; Rivory LP
    Clin Pharmacokinet; 1999 Feb; 36(2):99-114. PubMed ID: 10092957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
    Yamamoto N; Tamura T; Kamiya Y; Sekine I; Kunitoh H; Saijo N
    J Clin Oncol; 2000 Jun; 18(11):2301-8. PubMed ID: 10829051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
    Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
    Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
    J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
    Rosing H; Lustig V; van Warmerdam LJ; Huizing MT; ten Bokkel Huinink WW; Schellens JH; Rodenhuis S; Bult A; Beijnen JH
    Cancer Chemother Pharmacol; 2000; 45(3):213-8. PubMed ID: 10663639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
    Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
    Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
    van Zuylen L; Sparreboom A; van der Gaast A; van der Burg ME; van Beurden V; Bol CJ; Woestenborghs R; Palmer PA; Verweij J
    Clin Cancer Res; 2000 Apr; 6(4):1365-71. PubMed ID: 10778964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.
    Onoue H; Yano I; Tanaka A; Itohara K; Hanai A; Ishiguro H; Motohashi H; Masuda S; Matsubara K
    Eur J Clin Pharmacol; 2016 Jun; 72(6):703-10. PubMed ID: 26905999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of total and unbound etoposide.
    Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
    Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
    Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
    Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.